Patients With Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement

CSANZ Cardiovascular Genetic Diseases Council

Research output: Contribution to journalLetterpeer-review

4 Citations (Scopus)


In the context of the current global COVID-19 pandemic, this Consensus Statement provides current recommendations for patients with, or at risk of developing, genetic heart disease, and for their health care management and service provision in Australia and New Zealand. Apart from general recommendations, there are specific recommendations for the following conditions: cardiomyopathy, Brugada syndrome (including in children), long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). Other recommendations are relevant to patient self-care and primary health care.

Original languageEnglish
Pages (from-to)e85-e87
JournalHeart Lung and Circulation
Issue number7
Publication statusAccepted/In press - 14 May 2020


  • Brugada syndrome
  • COVID-19
  • Cardiomyopathy
  • Catecholaminergic polymorphic ventricular tachycardia
  • Genetic heart disease
  • Long QT syndrome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this